Terlipressin & Albumin Therapy in Hepatorenal Syndrome: A Comparative Analysis of Renal Function and Survival Outcomes
DOI:
https://doi.org/10.53350/pjmhs02025198.6Keywords:
Hepatorenal syndrome, Terlipressin, Albumin, Liver cirrhosis, Renal failure, Survival, Treatment outcomes.Abstract
Background: Hepatorenal syndrome is a syndrome of critical and life-threatening complications of advanced liver cirrhosis in which the renal dysfunction is not caused by underlying kidney disease. Telipressin in combination with albumin is also involved in enhancing renal dysfunction and survival in patients with hepatorenal syndrome.
Objective: To determine the effect of terlipressin and albumin on the improvement of renal functions, survival and adverse events in patients with hepatorenal syndrome type 1 and 2.
Methods: It was a retrospective cohort study that was conducted on 188 subjects, i.e., patients with hepatorenal syndrome who were prescribed with terlipressin (1 mg per 4 hours) and albumin (20-40 g per day) during the period 1st July 2024 and 28th March 2025 at the Department of Nephrology, University College of Medicine and Dentistry, The University of Lahore. Renal improvement in terms of a 30% decrease of serum creatinine was set as the main endpoint. Secondary outcomes were 30 and 6-month survival and the occurrence of adverse events.
Results: 45 % had hepatorenal syndrome type 1 and 55 percent had hepatorenal syndrome type 2. Renal performance improved in 62 percent of patients and 35 percent recovered their renal functions completely. The 30 days and 6 months mortality rates were 15 and 30 percent, respectively. The combination therapy was associated with a significant reduction of mortality in patients with type 1 hepatorenal syndrome (p=0.04). The number of adverse events was 13 percent in both hypertension and ischemic events.
Conclusion: Terlipressin combined with albumin is of significant benefit in enhancing renal activity and survival in patients with hepatorenal syndrome when administered in combination with albumin, and in patients with type 1 hepatorenal syndrome. The timing of treatment is very important to achieve good results.
References
Ginès P, Solà E, Angeli P, Wong F, Nadim MK, Kamath PS. Hepatorenal syndrome. Nat Rev Dis Primers 2018;4(1):23.
Wong F, Ielasi A, Parikh CR. Hepatorenal syndrome: pathogenesis and therapy. Hepatology 2020; 72(6): 1767-79.
Pappas SC, Blei AT. Hepatorenal syndrome: pathogenesis and management. Clin Liver Dis 2020; 24(3): 381-94.
O'Leary JG, Reddy KR, Garcia-Tsao G. The pathogenesis and management of hepatorenal syndrome. Hepatology 2022; 76(4): 1162-73.
Gines P, Guevara M, Arroyo V. The role of vasoconstrictors in the treatment of hepatorenal syndrome. J Hepatol 2016; 64(4): 944-56.
Fagundes C, Solis M, Loos B. Albumin and vasopressin in treatment of hepatorenal syndrome. Hepatology 2021; 73(1): 123-34.
Lim JK, Groszmann RJ. Vasoconstrictor therapy in hepatorenal syndrome. Gastroenterology 2008; 134(5): 608-11.
Belcher JM. Hepatorenal syndrome type 1: diagnosis and treatment. AKDH 2024; 31(2): 100-110
Fernandez J, Arroyo V, González-Moreno M. Outcome and long-term results in hepatorenal syndrome. J Hepatol 2018; 69(4): 786-94.
Pappas SC, Blei AT. Hepatorenal syndrome: pathogenesis and management. Clin Liver Dis 2020; 24(3): 381-94.
Gines P, Angeli P, Wong F, et al. Hepatorenal syndrome: pathogenesis and therapy. Hepatology. 2016; 64(4): 944-56.
Mattos ÂZ, Schacher FC, Mattos AA. Vasoconstrictors in hepatorenal syndrome - a critical review. Ann Hepatol 2019;18(2):287-90.
Maes M, De Bruyn G, Haerynck P. Treatment of type 1 hepatorenal syndrome with vasopressin analogs and albumin. J Hepatol 2019; 66(5): 1222-9.
Heidemann J,Bartels C,Berssenbrügge C, Schmidt H,Meister T. Hepatorenal syndrome: outcome of response to therapy and predictors of survival. Gastroenterol Res Prac 2015; 5: 1-6.
Feu F, Rodriguez-Frias F, Salo J. Terlipressin and albumin for the treatment of hepatorenal syndrome: a randomized controlled trial. Liver Transpl 2022; 28(10): 1441-52.
Nazar A, Pereira GH, Guevara M, Martín‐Llahi M, Pepin MN, Marinelli M, et al. Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology. 2010;51(1):219-26.
Licata A, Maida M, Bonaccorso A, Macaluso FS, Cappello M, Craxì A, et al. Clinical course and prognostic factors of hepatorenal syndrome: A retrospective single-center cohort study. World J Hepatol2013;5(12):685.
Downloads
How to Cite
Issue
Section
License
Copyright (c) 2025 ALI SAQLAIN HAIDER, ABDUL MATIN QAISAR, HUMAIRA SAMI ULLAH, NEHA AHUJA, ABAD-UR-REHMAN, KASHIF RIAZ
This work is licensed under a Creative Commons Attribution 4.0 International License.
